Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Felzartamab · MOR-202, MOR-03087

Monoclonal antibody · Immune activation, directed at CD38 · developed by BIOGEN

Phase 3 Most advanced trial

BIIB Developer

1 Registered trials

What is Felzartamab?

Felzartamab is a fully human monoclonal antibody that binds CD38 on tumor cells and immune cells. It triggers antibody-dependent cellular cytotoxicity (ADCC) leading to cell lysis. It is studied in antibody-mediated rejection and hematologic malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MOR-202, MOR-03087, TJ202, HIB202, BIIB148
Drug type: Monoclonal antibody
Targets: CD38
Mechanism: Immune activation, directed at CD38
Pathways: ADCC, apoptosis
Therapy area: Immunology
Developer: BIOGEN (BIIB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 3O9FA4XC02

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06685757	Phase 3	Antibody-mediated Rejection	Active not recruiting	BIIB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Antibody-mediated Rejection

Other drugs acting on CD38

ABBV-438 Phase 1 Mezagitamab Phase 3

More from BIOGEN

Dimethyl Fumarate FDA approved Diroximel Fumarate FDA approved Interferon Beta-1A FDA approved Natalizumab FDA approved Nusinersen FDA approved Omaveloxolone FDA approved Tofersen FDA approved Zuranolone FDA approved BIIB115 Phase 1 BIIB122 Phase 3 BIIB144 Phase 1 BIIB147 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BIIB page.

Follow BIIB, the company behind Felzartamab

See BIIB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIIB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z